Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

TCP-25 PU Dressing - An advanced bioactive wound dressing

Reference number
Coordinator in2cure AB
Funding from Vinnova SEK 1 445 000
Project duration September 2016 - November 2018
Status Completed

Purpose and goal

The purpose of the project was to develop and verify the effectiveness, regulatory pathway, and clinical potential of a novel wound dressing with anti-inflammatory and anti-infective effects. Of importance was also that we used generated data as input parameters for subsequent health economics analyses.

Expected results and effects

The effectiveness of TCP-25 gel was shown in large animal wound models. The subsequent health economics analyses showed that use of advanced dressings is a feasible approach in order to reduce total system costs for wound healing complications. On the regulatory side, we defined the regulatory pathway for TCP-25 products.

Planned approach and implementation

The project has included three parties, in2cure, Lund University and an industrial partner. The focus has been on evaluating in2cure´s wound treatment in large animal models, making a regulatory assessment of the concept, and evaluating the health-economic benefit of the treatment. The project has been regularly discussed in a steering committee with representatives from the various parties.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 10 December 2018

Reference number 2016-02343

Page statistics